BACKGROUND: Despite the substantial hospitalization costs associated with the management of patients with skin and soft tissue infections (SSTIs) in the inpatient setting, there is limited guidance on patients who should be managed in the hospital relative to the outpatient setting. Studies have demonstrated that SSTI patients without major complications or comorbidities can be successfully managed in the outpatient setting. However, there are limited data on current hospital admission patterns for patients with SSTI. OBJECTIVES: Given this literature gap, this study described the current hospital admission patterns among adult patients with SSTI using data from a US hospital research database. METHODS: To determine the subset of hospitalized SSTI patients who could likely be managed in the outpatient setting (potentially avoidable hospital admissions), the distribution of hospital admissions was categorized by infection severity and Charlson Comorbidity Index (CCI) score. RESULTS: During the study observational period, there were 610,867 medical encounters across 520 hospitals. Of the 610,867, 125,743 (20.6%) were treated as inpatients. Nearly all patients with life-threatening conditions or systemic symptoms or a CCI score of 2 or greater were admitted. Among those with no life-threatening conditions and no systemic symptoms, admission rates exceeded 10 and 30% for patients with a CCI score of zero and 1, respectively. While the admissions rates for these patient populations were low, they accounted for nearly 60% of all admissions (75,255 of 125,743 hospital admissions). On average, patients with CCI score of zero or 1, independent of the presence of systemic symptoms, were treated in the hospital for about 4 days, costing $6000-$7000 on average. CONCLUSIONS: Given the cost associated with the management of patients with SSTIs in the inpatient setting, the findings highlight the critical need for healthcare systems to develop well-defined criteria for hospital admission based on presence of comorbid conditions and infection severity.
BACKGROUND: Despite the substantial hospitalization costs associated with the management of patients with skin and soft tissue infections (SSTIs) in the inpatient setting, there is limited guidance on patients who should be managed in the hospital relative to the outpatient setting. Studies have demonstrated that SSTI patients without major complications or comorbidities can be successfully managed in the outpatient setting. However, there are limited data on current hospital admission patterns for patients with SSTI. OBJECTIVES: Given this literature gap, this study described the current hospital admission patterns among adult patients with SSTI using data from a US hospital research database. METHODS: To determine the subset of hospitalized SSTI patients who could likely be managed in the outpatient setting (potentially avoidable hospital admissions), the distribution of hospital admissions was categorized by infection severity and Charlson Comorbidity Index (CCI) score. RESULTS: During the study observational period, there were 610,867 medical encounters across 520 hospitals. Of the 610,867, 125,743 (20.6%) were treated as inpatients. Nearly all patients with life-threatening conditions or systemic symptoms or a CCI score of 2 or greater were admitted. Among those with no life-threatening conditions and no systemic symptoms, admission rates exceeded 10 and 30% for patients with a CCI score of zero and 1, respectively. While the admissions rates for these patient populations were low, they accounted for nearly 60% of all admissions (75,255 of 125,743 hospital admissions). On average, patients with CCI score of zero or 1, independent of the presence of systemic symptoms, were treated in the hospital for about 4 days, costing $6000-$7000 on average. CONCLUSIONS: Given the cost associated with the management of patients with SSTIs in the inpatient setting, the findings highlight the critical need for healthcare systems to develop well-defined criteria for hospital admission based on presence of comorbid conditions and infection severity.
Authors: Thomas P Lodise; Mark Redell; Shannon O Armstrong; Katherine A Sulham; G Ralph Corey Journal: Open Forum Infect Dis Date: 2017-01-19 Impact factor: 3.835
Authors: Safa S Almarzoky Abuhussain; Michelle A Burak; Kelsey N Kohman; Gabrielle Jacknin; Serina B Tart; Athena L V Hobbs; Danyel K Adams; Michael D Nailor; Katelyn R Keyloun; David P Nicolau; Joseph L Kuti Journal: BMC Health Serv Res Date: 2018-12-04 Impact factor: 2.655
Authors: Fredrick M Abrahamian; George Sakoulas; Evan Tzanis; Amy Manley; Judith Steenbergen; Anita F Das; Paul B Eckburg; Paul C McGovern Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Thomas P Lodise; Christina Palazzolo; Kerry Reksc; Elizabeth Packnett; Mark Redell Journal: Open Forum Infect Dis Date: 2019-11-04 Impact factor: 3.835
Authors: Kimberly Saddler; Jason Zhang; Jennifer Sul; Pruthvi Patel; Miriams Castro-Lainez; Mark L Stevens; Sheryl Kosler; Emily Lowery; Miguel Sierra-Hoffman Journal: PLoS One Date: 2021-03-18 Impact factor: 3.240